Search

Displaying results 8231 - 8240 of 10000 in total
  1. Drug

    alpha-Hydroxylinoleic acid

    go.drugbank.com/drugs/DB16027
    Investigational

    alpha-Hydroxylinoleic acid is under investigation in clinical trial NCT04431258 (ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study).

  2. Drug

    EPI-589

    go.drugbank.com/drugs/DB16041
    Investigational

    EPI-589 is under investigation in clinical trial NCT02460679 (Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)).

  3. Drug

    INCB-057643

    go.drugbank.com/drugs/DB16054
    Investigational

    INCB-057643 is under investigation in clinical trial NCT02959437 (Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)).

  4. Drug

    Ro 24-7429

    go.drugbank.com/drugs/DB16062
    Investigational

    Ro 24-7429 is under investigation in clinical trial NCT00002314 (A Study of Ro 24-7429 in Patients With Hiv-related Kaposi's Sarcoma).

  5. Drug

    Dotinurad

    go.drugbank.com/drugs/DB16145
    Investigational

    Dotinurad is under investigation in clinical trial NCT03372200 (Febuxostat-controlled, Double-blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout).

  6. Drug

    Plixorafenib

    go.drugbank.com/drugs/DB16038
    Investigational

    PLX8394 is under investigation in clinical trial NCT02428712 (A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors).

  7. Drug

    TMC-310911

    go.drugbank.com/drugs/DB15623
    Investigational

    [L12045] It is being investigated for use in HIV-1 infections. … [L12045,A191643] TMC-310911 is currently being investigated, in combination with other HIV therapies and antivirals, as a potential treatment for COVID-19 caused by SARS-CoV-2.[L12012]

  8. Drug

    NPI 32101

    go.drugbank.com/drugs/DB05264
    Experimental

    NPI 32101 possesses both anti-inflammatory and broad spectrum antimicrobial activities. This combination of pharmacological properties may have additional therapeutic uses beyond dermatology.

  9. Drug

    Apomab

    go.drugbank.com/drugs/DB15022
    Investigational

    Apomab is under investigation in clinical trial NCT00851136 (A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced

  10. Drug

    G305

    go.drugbank.com/drugs/DB17292
    Investigational

    G305 is a [recombinant NY-ESO-1 protein] plus glucopyranosyl lipid A (GLA) in a stable emulsion (SE). G305 is an active component of CMB305 along with [LV305].[L47346]